Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCA33890 in Advanced or Metastatic Solid Tumors
NCT05836324Phase 1Recruiting
- Sponsor
- Incyte
- Start
- Jul 2023
- Primary completion
- May 2029
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 1, open-label trial of INCA-33890 in solid tumor (12 arms), sponsored by Incyte. Primary endpoints: Dose Limiting Toxicities at 28 days, Treatment Emerging Adverse Events at 2 years and 1 more. Started Jul 2023; status: recruiting.
02
Drugs
INCA-33890
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05836324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05836324.